Beacon Biosignals is a AI / Neuroscience / Healthcare. IPO Status: Pre-IPO. IPO Readiness Score: 57/100 (C-).
Beacon Biosignals IPO status, timeline, valuation and S-1 filing tracker. Last updated May 2026.
| Industry | AI / Neuroscience / Healthcare |
| Stage | series_b |
| IPO Status | Pre-IPO |
| Total Funding | ~$132M |
| Headquarters | Boston, MA |
| IPO Readiness Score | 57/100 |
Track Beacon Biosignals IPO status, valuation updates, and S-1 filing milestones on TechStackIPO. Last updated May 2026.
AI-powered neuroscience platform analyzing brain signals for clinical and pharma applications
Beacon Biosignals is in the pre-IPO phase as of May 2026. The company has an IPO readiness score of 57/100, suggesting it may be 1–3 years from a public listing depending on market conditions and internal milestones. Pre-IPO companies at this stage typically evaluate market conditions, complete board appointments, and engage underwriters before initiating the formal S-1 filing process.
Beacon Biosignals has raised ~$132M in total funding. While a formal valuation has not been publicly disclosed, the company’s funding history suggests meaningful investor confidence. IPO valuations are typically set during the roadshow process and reflect both private market precedents and public market conditions at the time of listing.
Accredited investors may be able to access Beacon Biosignals pre-IPO shares through secondary market platforms. These platforms facilitate private share transactions between existing shareholders (employees, early investors) and new buyers.
Risk factors: Pre-IPO investments are illiquid, carry higher risk than public market investments, and are typically restricted to accredited investors. Share availability and pricing depend on current shareholders willing to sell. TechStackIPO provides data and tracking tools but does not facilitate or recommend investments.
Funding rounds from seed through latest — Series A, B, C and beyond.
| Round | Date | Amount | Valuation | Lead Investor(s) |
|---|---|---|---|---|
| Series B Extension | Apr 2026 | $97.2M | — | JSL Health, Palo Santo |
Total funding raised: ~$132M
Beacon Biosignals has an IPO readiness score of 57/100 on TechStackIPO. A moderate readiness score suggests the company may be 2–4 years from IPO.
Pre-IPO access options may include: (1) secondary market platforms such as Forge Global or EquityZen that facilitate private share sales, (2) ETFs holding pre-IPO companies or venture portfolios, and (3) direct secondary share purchases if eligible as an accredited investor. TechStackIPO tracks availability but does not facilitate investments.
No. Beacon Biosignals has not yet filed an S-1 registration statement with the SEC as of TechStackIPO's latest data update.
Beacon Biosignals operates in the AI / Neuroscience / Healthcare sector. TechStackIPO tracks multiple AI / Neuroscience / Healthcare companies from seed through IPO, including their funding rounds, valuations, and IPO readiness scores. You can compare Beacon Biosignals against other AI / Neuroscience / Healthcare companies using TechStackIPO's comparison tool.
Beacon Biosignals is at the series_b stage. The company has raised a total of ~$132M in funding. Companies at this funding stage are typically scaling operations, expanding market share, and evaluating public market timing.
Beacon Biosignals is headquartered in Boston, MA. The company's location can influence IPO exchange selection, regulatory requirements, and investor interest. Companies headquartered in major tech hubs often benefit from proximity to venture capital networks and talent pools.